Krause P R
Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.
Arch Virol Suppl. 2001(17):7-15. doi: 10.1007/978-3-7091-6259-0_2.
Serum antibody levels and infection rates were followed for 4 years in 4,631 children immunized with the recently licensed Oka strain varicella vaccine. Anti-VZV titers declined over time in high-responder subjects, but rose in vaccinees with low titers. Among subjects with low anti-VZV titers, the frequency of clinical sequelae and immunological boosting significantly exceeded the 13%/yr rate of exposure to wild type varicella. These findings indicate that the Oka strain of VZV persisted in vivo, and reactivated as serum antibody titers declined after vaccination. This mechanism may improve vaccine-associated long-term immunity.
对4631名接种了最近获批的Oka株水痘疫苗的儿童进行了4年的血清抗体水平和感染率跟踪。高反应者的抗VZV滴度随时间下降,但低滴度疫苗接种者的滴度上升。在抗VZV滴度低的受试者中,临床后遗症和免疫增强的频率显著超过每年13%的野生型水痘暴露率。这些发现表明,VZV的Oka株在体内持续存在,并在接种疫苗后随着血清抗体滴度下降而重新激活。这种机制可能会改善疫苗相关的长期免疫力。